论文部分内容阅读
目的:观察糖皮质激素联合贝那普利在IgA肾病治疗中的价值。方法:选取IgA肾病42例,随机分为观察组(泼尼松+贝那普利)22例和对照组(贝那普利)20例。治疗6个月后对比分析两组的临床疗效,并记录两组治疗前后尿蛋白、血肌酐(SCr)和血尿素氮(BUN)的变化。结果:观察组的总显效率77.3%显著高于对照组的55.0%(P<0.05);观察组治疗后24h尿蛋白定量、SCr、BUN水平均显著低于对照组(P<0.05);两组治疗期间不良反应发生率差异不显著(P>0.05)。结论:糖皮质激素联合贝那普利治疗IgA肾病,效果优于单独应用贝那普利。
Objective: To observe the value of glucocorticoid combined with benazepril in the treatment of IgA nephropathy. Methods: Forty-two patients with IgA nephropathy were randomly divided into observation group (prednisone + benazepril) and control group (benazepril), 22 cases. After 6 months of treatment, the clinical efficacy of the two groups were compared and the changes of urinary protein, serum creatinine (SCr) and blood urea nitrogen (BUN) were recorded before and after treatment. Results: The total effective rate of observation group was 77.3%, which was significantly higher than that of control group (55.0%, P <0.05). The levels of urinary protein, SCr and BUN in observation group were significantly lower than those in control group (P <0.05) There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). CONCLUSION: Glucocorticoid combined with benazepril is superior to benazepril alone in the treatment of IgA nephropathy.